The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

According to the Federal Trade Commission, UnitedHealth Group has been charging patients markups on lifesaving drugs. Between ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...

The updated tally extends the scope beyond what was previously described by company Chief Executive Andrew Witty.

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

UnitedHealth Group is charging patients a markup for key life-saving drugs that could easily exceed their cost by a factor of ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...